What Cancers Are Associated With High RDW?

Elevated red cell distribution width, or RDW, has been linked to worse outcomes across a surprisingly broad range of cancers, including colorectal, lung, breast, ovarian, gastric, esophageal, and bladder malignancies. RDW measures how much your red blood cells vary in size. A normal value typically falls between about 11.5% and 14.5%, and when it climbs higher, it signals that something is disrupting the way your body produces or maintains red blood cells. That disruption turns out to be a common thread in many cancers, which is why researchers have spent the past decade investigating RDW as a cheap, readily available prognostic marker in oncology.

Why Cancer Drives RDW Higher

RDW is part of a standard complete blood count, the routine blood test you get at nearly every doctor’s visit. It reflects impaired red blood cell production and abnormal red blood cell survival.¹ In cancer, several forces push RDW upward simultaneously. Chronic inflammation floods the bloodstream with cytokines that interfere with how the bone marrow produces red blood cells. Tumors also compete with healthy tissue for iron and other nutrients, creating the kind of nutritional shortfalls that produce oddly sized red blood cells. On top of that, many cancers cause slow, invisible bleeding, particularly in the gastrointestinal tract, which gradually depletes iron stores and triggers the marrow to release immature red blood cells of varying sizes into circulation.

This combination of inflammation, nutritional theft, and occult blood loss means RDW can rise well before a patient shows obvious symptoms of anemia. That is part of what makes it interesting to researchers: it is not a cancer-specific test, but it picks up systemic stress signals that many cancers share.

Colorectal Cancer

Colorectal cancer is probably the best-studied cancer in relation to RDW, and the findings are consistent. A large analysis using nearly two decades of U.S. national health survey data found that people in the highest quarter of RDW values had roughly two and a half times the risk of colon cancer compared to those in the lowest quarter, after adjusting for other factors. The same high-RDW group also had nearly triple the risk of dying from any cause.² That association between elevated RDW and death is not just about having cancer in the first place; it persists even after accounting for the cancer diagnosis.

The prognostic signal holds up after surgery, too. In patients with early-stage colorectal cancer who had curative resection, those with high preoperative RDW had worse overall survival, disease-free survival, and cancer-specific survival. Even after researchers used statistical matching to balance confounding factors like age, diabetes, and kidney disease, high RDW remained an independent negative predictor of overall survival.³ A separate study from Bali found that a preoperative RDW above roughly 13.6% was an independent mortality factor in colorectal cancer patients, alongside late stage and poor tumor differentiation.⁴

What makes colorectal cancer a natural candidate for RDW research is that chronic intestinal bleeding is a hallmark of the disease. Even small polyps and early tumors can ooze blood into the gut, gradually shifting the size distribution of red blood cells before a patient ever notices blood in the stool. RDW may therefore flag a problem earlier than hemoglobin alone, which can stay in the normal range for a while thanks to compensatory mechanisms in the bone marrow.

Lung Cancer

In advanced non-small cell lung cancer, patients with elevated RDW had shorter progression-free survival than patients with normal RDW. One study reported a median progression-free survival gap of roughly 46 days between the two groups.⁵ That may not sound dramatic on its own, but in advanced lung cancer, where median survival is already measured in months, any measurable difference in a routine blood marker is worth attention.

Lung cancer’s relationship with RDW probably reflects the intense systemic inflammation these tumors generate. Lung cancers are well known for producing inflammatory mediators that suppress the bone marrow, and patients with advanced disease often have poor nutritional status. Both factors push RDW upward. A Mendelian randomization study has explored whether the relationship is causal or just correlational, though the evidence for a direct causal link remains preliminary.⁶

Breast Cancer

High preoperative RDW has been tied to worse outcomes in breast cancer as well. In a retrospective cohort of breast cancer patients, those in the high-RDW group were far more likely to have advanced-stage disease at diagnosis: about a third of the high-RDW group had stage III disease, compared to a quarter in the low-RDW group. The pattern was even more striking at stage I, where only about 10% of the high-RDW group presented, versus 35% of the low-RDW group. After adjusting for other variables, high RDW was independently associated with poorer overall survival and disease-free survival.⁷

Researchers have also explored combining RDW with platelet count to form a composite ratio, the RDW-to-platelet ratio (RPR). In one breast cancer study, patients with an elevated RPR had a five-year disease-free survival rate of about 78%, compared to roughly 90% in the low-RPR group. On multivariate analysis, the RPR was a stronger predictor of recurrence than RDW alone.⁸ The idea behind combining RDW with other blood values is that inflammation affects multiple cell lines at once, and a ratio can capture that systemic disruption more sensitively than any single number.

Ovarian Cancer

Ovarian cancer is notoriously difficult to detect early, which is why any cheap, accessible screening signal attracts interest. RDW values are significantly higher in ovarian cancer patients compared to healthy controls and to patients with benign ovarian tumors.⁹ RDW also correlates positively with cancer stage, meaning it tends to be higher the more advanced the disease.

One study found that RDW had an area under the curve of 0.876 for distinguishing ovarian cancer patients from controls, which is a reasonably strong diagnostic performance for a single routine blood test parameter. RDW was also positively correlated with CA-125 (the traditional ovarian cancer marker), the neutrophil-to-lymphocyte ratio, and the platelet-to-lymphocyte ratio, while being negatively correlated with hemoglobin.¹⁰ Nobody is suggesting RDW should replace CA-125 or imaging, but the fact that it tracks so closely with disease stage and established markers suggests it could add value as a supplemental screening tool, particularly in settings where advanced testing is unavailable or unaffordable.

Gastric and Esophageal Cancers

The upper gastrointestinal tract follows a similar pattern. In gastric cancer, high RDW is associated with poor survival, and researchers have proposed it as a monitoring marker for disease progression.¹¹ Like colorectal cancer, stomach tumors frequently bleed, creating the same iron depletion and compensatory marrow response that inflates RDW. The nutritional component is especially pronounced in gastric cancer because the tumor itself can impair absorption of iron, folate, and vitamin B12 from food.

In esophageal cancer, a retrospective study of patients who underwent esophagectomy found that high preoperative RDW independently predicted worse overall survival, with a hazard ratio of about 1.47. High RDW was also associated with lower body mass index, lower hemoglobin, lower albumin, and worse overall nutritional status.¹² The tight relationship between RDW and nutritional markers in esophageal cancer reinforces the idea that RDW is partly a proxy for how malnourished and inflamed the body has become. Esophageal cancer patients often struggle to eat, and by the time they reach surgery, severe weight loss and protein depletion are common.

Researchers have also tested combining RDW with albumin to form the RDW-albumin ratio (RAR) for gastric cancer prognosis. The RAR consistently outperformed other inflammatory ratios like neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios over follow-up, though its overall predictive power remained modest on its own.¹³ This is a running theme across the RDW-cancer literature: RDW adds useful prognostic information, but it works best as one piece of a larger puzzle rather than a standalone predictor.

Bladder Cancer

In bladder cancer, elevated preoperative RDW has been linked to worse survival after radical cystectomy. One study found significant differences in overall survival, cancer-specific survival, and disease-free survival between high- and low-RDW groups.¹⁴ A separate retrospective analysis showed that patients who died had substantially higher median RDW values than survivors (about 14.8% versus 13.6%), and elevated RDW remained an independent predictor of mortality after adjusting for age and other factors.¹⁵

Bladder cancer is an interesting case because it does not typically cause the kind of chronic blood loss you see in gastrointestinal cancers. The RDW elevation in bladder cancer patients probably reflects systemic inflammation and the general metabolic disruption that accompanies the disease, rather than nutritional depletion from bleeding alone. This supports the view that inflammation is the dominant driver of RDW changes across cancer types, with bleeding as a compounding factor in certain tumors.

What the Meta-Analyses Show

Individual cancer-site studies are useful, but the most convincing evidence that RDW matters broadly in oncology comes from pooled analyses. A meta-analysis that combined 16 studies involving over 4,200 cancer patients found that elevated RDW was associated with poorer overall survival across cancer types, with a pooled hazard ratio of 1.47.¹⁶ In practical terms, that means patients with high RDW had roughly 47% greater risk of death over the study periods compared to those with normal values, after accounting for other variables. The signal was not limited to one organ or tumor type.

That said, this is far from the strongest prognostic marker available in oncology. Tumor stage, grade, and molecular subtype remain the dominant predictors of outcome for most cancers. What RDW offers is something different: it is universally available, costs almost nothing extra (it is already part of a standard blood count), and can be tracked over time without any special equipment.

Tracking RDW Changes During Treatment

One of the more practical applications of RDW is monitoring how it changes during treatment rather than just looking at the preoperative value. In colorectal cancer patients, researchers found that both the baseline RDW and the change in RDW (the difference between pre- and post-treatment values) were independent predictors of survival. Patients whose RDW rose during or after treatment had worse overall survival than those whose RDW stayed stable or dropped.¹⁷

This dynamic tracking approach makes intuitive sense. If RDW reflects the body’s inflammatory and nutritional burden, then a rising RDW during treatment may indicate that the cancer is not responding, that the treatment itself is causing significant physiological stress, or that a recurrence is brewing. Conversely, a falling RDW may signal that treatment is reducing the tumor’s systemic effects. Oncologists do not yet use RDW changes as a formal treatment response marker, but the concept of tracking trends rather than just snapshots is gaining traction in the research literature.

RDW and Chemotherapy-Related Heart Damage

An unexpected application of RDW has emerged in cardio-oncology, the field concerned with heart damage caused by cancer treatments. Anthracyclines, a class of chemotherapy drugs used for breast cancer, lymphomas, and other malignancies, are well known for their potential to damage the heart. One study found that patients with higher baseline RDW values before starting anthracycline therapy had a much greater rate of chemotherapy-related cardiac dysfunction: about 11.5% in the high-RDW group versus 2% in the low-RDW group. RDW was an independent predictor of developing heart toxicity from the treatment.¹⁸

This finding is particularly relevant because identifying patients at high risk for cardiac toxicity before chemotherapy starts could change clinical decisions. Patients with elevated RDW might warrant closer cardiac monitoring, alternative chemotherapy regimens, or earlier intervention with cardioprotective drugs. It also hints at a broader principle: RDW captures a general state of physiological vulnerability, not just cancer-specific risk. A body that is already inflamed and nutritionally depleted may be less resilient against the side effects of aggressive treatment.

What High RDW Does Not Tell You

For all its promise, RDW has real limitations that are worth understanding. The biggest one is that it is profoundly nonspecific. Dozens of conditions raise RDW, and most of them have nothing to do with cancer. Iron deficiency from a poor diet, vitamin B12 or folate deficiency, chronic kidney disease, liver disease, heart failure, autoimmune disorders, recent blood transfusions, and even heavy alcohol use can all push RDW above normal. A high RDW on a routine blood test is far more likely to reflect one of these benign conditions than an underlying malignancy.

This means RDW is useful for prognosis in people who already have a cancer diagnosis, but it is not useful for screening healthy people for cancer. Finding a high RDW in someone without known cancer should prompt investigation of the common causes first. Only if those are ruled out and other red flags are present does the cancer association become relevant. Even the most enthusiastic researchers in this area acknowledge that larger studies are needed before these findings can be generalized, and that RDW works best as supplemental prognostic information added on top of standard cancer staging, not as a replacement for any of it.¹

There is also the confounding problem. Patients with high RDW tend to be older, more malnourished, and sicker in general. Even after statistical adjustments, it is difficult to fully disentangle whether RDW itself is driving the worse outcomes or whether it is simply a marker of overall frailty. A patient with high RDW, low albumin, and poor nutritional status is going to do worse after major surgery for reasons that have nothing to do with red blood cell size variation. The esophageal cancer data makes this especially clear: high RDW tracked tightly with low body mass index, low albumin, and poor performance status, all of which independently predict worse outcomes.¹²

Where RDW Fits in Practice

The appeal of RDW as a cancer biomarker is mostly about accessibility. Tumor genomics, liquid biopsies, and advanced imaging are powerful but expensive and not available everywhere. RDW is reported on virtually every complete blood count drawn anywhere in the world. In resource-limited settings where molecular profiling is out of reach, RDW can help stratify patients into higher- and lower-risk groups using data that already exists in their medical records. It requires no extra blood draw, no special equipment, and no additional cost.

In wealthier healthcare systems, RDW is more likely to play a supporting role. A surgeon deciding between two otherwise similar colorectal cancer patients might use preoperative RDW alongside albumin and performance status to gauge who needs more aggressive monitoring post-surgery. An oncologist starting anthracycline chemotherapy might factor baseline RDW into the cardiac risk assessment. These are incremental gains in risk prediction, not revolutionary diagnostic tools. But in a field where marginal improvements in prognostication translate into better-tailored care, marginal gains from a free test are hard to argue against.

The composite biomarker approach, combining RDW with platelet count, albumin, or other routine values, represents the direction most researchers are heading. No single routine blood value carries enough predictive weight to stand alone in cancer prognosis. But combinations of cheap, universally available markers may eventually rival some of the more expensive prognostic tools currently in use. Whether that potential pans out will depend on large, prospective validation studies, which are still largely absent from this literature. Most of what we know comes from retrospective analyses, where selection bias and unmeasured confounders are always lurking.